Industry Briefs: May 14, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
Industry Briefs: May 14, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
May 17, 2012

Company News

Almac has added the new PharmaWorks TF3, high-speed, large-format blister equipment, at its US headquarters in Souderton, Pennsylvania. Read More

GE Healthcare Life Sciences has completed its acquisition of Xcellerex. Read More

Molecular Profiles and GEA Process Engineering are collaborating to improve early screening of poorly water-soluble drugs and polymer compositions using the GEA Niro Drynetics single-particle spray-drying application.

Novozymes Biopharma has started to supply Novozymes Hyasis, a pharmaceutical-grade hyaluronic acid, from its recently opened facility in Tianjin, China. Read More

NSF-DBA has agreed with the Semler Research Center to expand pharmaceutical training, auditing, consulting, and testing services throughout India. Read More

People News

Cytovance Biologics has named Martin LeBlanc to its board of directors. Read More

Incline Therapeutics has appointed John Tucker as senior vice-president and chief commercial officer. Read More

Teva Pharmaceutical has appointed Michael Hayden as president of global R&D and chief scientific officer Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Featured Jobs

More Jobs
5/17/2012
 Click here